‘Discussing Enhancing Sexual Performance with Stem Cell Therapy’ Feb. 17 at Noon

SUNRISE, FL – Feb. 14, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will host a live webinar open to the public with Ben Greenfield — a leading biohacker and fitness expert and CEO of health company Kion— who recently had penile stem cell injections to enhance sexual performance.

“Enhancing Sexual Performance with Stem Cell Therapy,” will be a live-streamed discussion and Q & A with Dr. Comella and Greenfield Saturday, Feb. 17, at Noon EST.  To participate in the webinar, please register by clicking on the link here: https://attendee.gotowebinar.com/register/7172776642688626689.

Greenfield, a self-professed ‘biohacker’ who recently received stromal vascular fraction treatments (SVF) for erectile enhancement as part of his ongoing exploration of optimal physical performance, including penile enhancement, says as a result of the treatment he has experienced penile enlargement and more frequent erections.  

“My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”

“Because so many patients are seeking holistic alternatives to sustain sexual performance, and because it’s Valentine’s Day, we thought it would be the perfect opportunity to discuss the use of autologous stem cells in this arena,” said Dr. Kristin Comella, USRM’s Chief Science Officer.  “Ben’s experience and his willingness to be open about sharing his journey will give a lot of people the opportunity to ask questions in an anonymous setting, so that they can learn more about whether the benefits of SVF is right for them.”

SVF involves using USRM’s proprietary AdipocellTM kit to help isolate a patient’s own stem cells from their fat cells. Studies of stromal vascular fractions used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

Autologous stem cell treatments harvested from the patient’s own fat could provide healthier alternatives to the use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a worldwide market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. As a result, more men and women are seeking out stem cell therapy to enhance sexual performance, which to date has yielded more than 35 scientific studies about stem cell therapy and sexual enhancement.

“Enhancing Sexual Performance with Stem Cells,” is the second in a series of webinars by USRM and Dr. Comella, dedicated to educating, informing and demystifying the public about the practice of regenerative stem cell therapy.  The first webinar, “Facts About Stem Cell Therapy,” which was broadcast live last Friday, can be accessed as a playback here.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Open to Global Participation, More than 100 Attendees in First Q & A

SUNRISE, FL – Feb. 12, 2018 – Dr. Kristin Comella, Chief Science Officer of U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the successful launch of an open, livestream webinar series designed to inform and educate the public on the benefits and applications of stem cell therapy.

“Facts About Stem Cell Therapy,” which had its first live broadcast last Friday and includes a question & answer session from more than 100 patients and physicians around the world, continued for nearly two hours while live streamers posted questions to Dr. Comella about the application of autologous stem cells therapy.   Such a strong, positive response demonstrates the growing demand for information about this emerging, holistic, regenerative therapy.

Playback of the webinar can be accessed here:

http://www.brainshark.com/Stemlogix/vu?pi=zHEz136Dfmz5OLvz0.

Dr. Comella will be hosting a second livestream webinar Saturday, Feb. 17, at 12 noon EST (Click here to register).  In honor of Valentine’s Day and the month of love, her featured guest will be fitness expert Ben Greenfield, who recently underwent stem cell therapy for erectile enhancement — a multi-million-dollar industry that is increasing in patient population but is underserved, mainly due to side effects associated with erectile dysfunction pharmaceuticals currently on the market.

“The webinar platform gives us the perfect opportunity to make the concept of autologous stem cell therapy accessible to the world,” said Dr. Comella.  “It also enables audience participation in a manner that allows for privacy.  I read the questions to the audience, so we maintain privacy from the inquisitor while simultaneously providing the opportunity for a comprehensive teaching moment, even in playback.  It’s a perfect way to help people learn more about this incredible form of healing.”  

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, is also featured in the recent Jeff Hays docuseries “The Healing Miracle: The Truth About Stem Cells.” (Click here to view Dr. Comella’s interview from THM in its entirety.)  It was her participation in the docuseries that inspired her to launch the webinar series.

“Dr. Comella is a natural — her passion is contagious and her expertise in stem cell therapy is unparalleled,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “Because demand has been so strong at our clinics, as more and more people are learning about stem cell therapy as an alternative to pain management, the webinar format gives us the opportunity to reach more people faster, and to meet the demand for more specific information in a really efficient and effective way.”

USRM has been involved in more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM, as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Failure of Opioids & Economic Growth Driving Force,

CSO to Host Live Info Webinar

SUNRISE, FL – Feb. 6, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it is experiencing explosive demand for stem cell treatments at its clinics — a trend that is reflected in the 106% increase in revenues during the 3rd Q and is continuing as a result of rapidly increasing demand from the marketplace.

As a result, USRM Chief Science Officer Dr. Kristin Comella, who is featured in the docuseries, “The Healing Miracle: The Truth About Stem Cells,” will be hosting a live webinar Friday, Feb. 9, to help answer questions about stem cell therapy and treatments.

“Our phones are ringing off the hook,” said Dr. Comella.  “Public demand is ramping up quickly, as Americans invest in educating themselves on stem cell therapy and alternatives to opioid protocols for chronic pain.  Moreover, because stem cell therapy is an out-of-pocket expense, improved economic indicators are giving Americans more money in their pockets for discretionary spending, which is increasing opportunity for stem cell treatments,” said Dr. Comella.

Total revenue for 2017, which will be announced in mid March when the company files its 10k, is expected to increase from 2016.

“We have seen significant revenue increases for the past six straight quarters and market demand is starting to drive revenue even further” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “We look forward to sharing news of our continued growth and are pleased to see 2018 is starting off so well with the recent milestone of reaching 10,000 units sold for our proprietary AdipocellTM product,” said Tomas.  “We believe this is an indicator of continued growth to come.”

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, can be seen in The Healing Miracle docuseries here.  To view Dr. Comella’s interview online, click the link and fill out the information, which will provide complimentary access.

To access Dr. Comella’s live webinar this Friday, Feb. 9, at Noon EST, click here to register or join.  Details of the webinar, along with a playback link after it is broadcast, will also be posted on the company’s website and its Facebook page (https://www.facebook.com/USStemCellInc/).

USRM has been involved in more than 10,000 stem cell procedures since 1999 for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM, a stem cell kit which enables physicians to separate potent stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years; has more than 287 clinics using its proprietary technology and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

SUNRISE, FL – Jan. 24, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, has been featured in the docuseries, “The Healing Miracle: The Truth About Stem Cells” — a film that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy.

Dr. Comella, who has more than 20+ years’ experience and is one of the world’s leading stem cell scientists, has been involved in more than 10,000 stem cell procedures at USRM since 2001.  USRM has pioneered stem cell therapy for damaged tissue from a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.  USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide —  and has engaged with more than 287 clinics.  Dr. Comella is well published in the scientific literature and has been recognized by her peers as an innovator and world leader in the development and clinical practice of stem cell products and therapies.  She has also been instrumental in developing and bringing to market USRM’s AdipocellTM , a stem cell kit which enables physicians to separate stem cells from a patient’s own fat cells, which are harvested and reinserted in a minimally invasive, two-hour procedure without general anesthesia.

In the documentary, Dr. Comella (who has worked with all kinds of stem cells including, bone, muscle and fat), recounts an emotional experience with a patient who presented with a two-year-old head trauma and was wheelchair bound.   Following her stem cell protocol with Dr. Comella and USRM, she had a life-changing experience.

Americans in general have been relatively uninformed about the availability of the field of stem cell therapy and regenerative medicine as an option for treating chronic pain conditions, damaged tissue and life-threatening illness. ‘The Healing Miracle,’ which is produced by Jeff Hays Films, is on a mission to change that trend by shining a light on a field of medicine that has been somewhat sidelined by U.S. regulatory agencies.  Last November, the FDA issued a long-awaited statement indicating it is moving toward integrating stem cell therapy into its code of practice, but concluded by giving itself three years to determine whether it will heavily regulate stem cells in humans as drugs, or continue to allow individuals to have free access to their own healing reserves of stem cells.

“The purpose of this interview is to educate people about cellular medicine — a concept that has been overshadowed by a pharmaceutical industry that has used disassociation and fear to distract patients from their own healing capabilities,” said Dr. Comella.  “This documentary is a great way for the public to learn more about regenerative options available to them —  an alternative to chronic, long-term drug use to managing symptoms, which we all know is often accompanied by debilitating side effects.  There has never been a better time to bring this forward than now, to explore healing regenerative therapies… facing a national emergency around pain management and opioid misuse is a clear wake up call that it’s time for better methods.”

Dr. Comella is featured in episode 5 of the docuseries, which is available in its entirety online.  To watch just Dr. Comella’s interview, click the Brainshark link here and fill out the information which will provide complimentary access.

“We are so proud of Dr. Comella. The world’s growing interest in her work and about stem cell therapy and regenerative medicine is an indication our time has come,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “Stem cell therapy is rapidly becoming a part of mainstream medicine, and USRM is poised to take the lead in offering this treatment worldwide.”

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide. 

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

Company Poised to Be Industry Leader in Autologous Adipose Stem Cell Treatments

SUNRISE, FL – Jan. 15, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced it has reached a key milestone of 10,000 kit sales of its proprietary Adipocell TM product, a direct result of its relationships with 287 clinics in the United States and 700+ physicians worldwide offering USRM’s proprietary stem cell products and services.

Adipocell TM , which has been developed, marketed and distributed by USRM, enables physicians to separate potent stem cells from a patient’s own (autologous) fat cells, which are harvested and reinserted in two-hours total, in a minimally invasive procedure. Stem cells are an important component of the body’s ability to regenerate itself, and are rapidly becoming a mainstream trend in the field of regenerative medicine.

USRM is the premiere company in the United States that markets and manufactures an autologous adipose/stem cell separation kit. Autologous cells are not rejected by the body’s immune system and, as a result, may be more compatible and effective in reversing damage and augmenting health.

In addition to trailblazing the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, USRM also has developed a training program for physicians who want to learn how to offer stem cell therapy to their patients.

In-person training involves a two-day, interactive, hands-on training course at USRM’s Sunrise, Florida-based clinic, and includes integration of autologous cellular treatments, the extraction of lipoaspirate and bone marrow aspirate, as well as demonstrations on how to isolate adipose and bone-marrow-derived stem cells. Physician trainees will participate in several cases and perform clinical procedures under the supervision of an experienced instructor on a total of 3-5 patients. Cost for physician participation is $7,500.

Online training offers physicians clinical training in a web-based format. Consistent with in-person training, online training focuses on autologous cellular treatments like adult stem cells and platelet-rich plasma. Physicians will learn the basics of stem therapy and have the option to obtain preceptor on-site training. Cost for physician participation is $2,500.

On-site training is available for physicians who have completed in-person or online training, and involves a USRM stem-cell specialist providing the physician one-on-one, on-site training at the physician’s own clinic.

“This is a key milestone for us as a Company, and for regenerative medicine in general, as it demonstrates the increasing demand in the marketplace for our AdipocellTM product,” said Mike Tomas, President and CEO of U.S. Stem Cell, Inc. “We are dedicated and proud to lead the way on a global scale for the emergence of this novel therapeutic.”

“Our commitment to making regenerative, stem cell therapy available to any physician worldwide who is interested in providing stem cell therapy to their patients is reflected in our day-to-day practices as an organization,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. “The need for readily available stem cell procedures that physicians can offer their patients as an alternative to addictive pain medications, which has caused an opioid crisis in America, proves the time for regenerative medicine as a part of regular physician practice and pain management is long overdue.”

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product AdipocellTM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

World-Renowned Athlete Receives Treatment, Featured in Men’s Health Magazine

SUNRISE, FL – Jan. 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement. Details of the procedure and the results are featured in the January issue of Men’s Health, on newsstands now.

Greenfield, whose experience following the treatments includes more frequent erections and penile enlargement, received his first of two treatments at the USRM clinic in Sunrise, Florida.

Stromal vascular fraction treatments, or autologous stem cell treatments harvested from the patient’s own fat, could provide healthier alternatives to use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. Greenfield, who is a self-professed ‘biohacker,’ sought treatment as part of his ongoing exploration of ‘biohacking’ and penile enhancement. “My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”

Stromal vascular fraction involves using USRM’s proprietary AdipoCellTM kit to help isolate a patient’s own stem cells from the fat cells. Studies of stromal vascular fraction’s used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.

“Autologous stem cell therapy is rapidly entering the arena of mainstream regenerative medicine, as is exemplified by its acceptance, use and promotion by cutting edge biohackers and fitness experts like Mr. Greenfield,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “As regenerative stem cell therapy continues to expand into specialized markets, we look forward to broadening our application for these voluntary procedures.”

Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.

“Last year was about restructuring debt and streamlining our financials in order to position ourselves in 2018 for these kinds of opportunities,” said Mike Tomas, USRM’s Chief Executive Officer. “We look forward to continuing to explore the application of stromal vascular fraction treatments for a wide variety of voluntary procedures which is being driven by market demand for more holistic, autologous therapies.”

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

MIAMI, FL –Dec.20, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today responded to a lawsuit filed last week in Broward County by a plaintiff claiming she had an adverse event for a voluntary stem cell procedure at a doctor’s office utilizing autologous (the patient’s own) stem cells to attempt to reverse the effects of macular degeneration— a disease that currently has no cure.

The adverse event the plaintiff claims she experienced as a result of the treatment, which was administered by a doctor in February of 2015, is a detached retina in one eye, which the patient alleges has led to loss of sight in that eye. Counsel for the patient also claims that his client’s vision has worsened in the other eye. As the lawsuit was just filed, these allegations have not been corroborated. USRM’s AdipoCell TM kit was used to harvest autologous cells from the patient’s fat tissue.

The use of autologous stem cells for macular degeneration was discontinued by US Stem Cell Clinic, a separate company, as of June of 2015, after adverse events were reported.

“We have addressed any concerns about using AdipoCell TM for macular degeneration by discontinuing its use since more than two years ago,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “Because we have seen strong safety profiles using AdipoCell TM to harvest autologous stem cells to treat a wide variety of other conditions — including orthopedic, autoimmune, degenerative and neurological diseases — we are instead focusing our development at this time on these more broad arenas.”

“Publicly traded companies are always a target for law suits,” said Mike Tomas, President & CEO of U.S. Stem Cell, Inc. “Every lawsuit is different, we are confident that our attorneys — who are very familiar with the issues surrounding this case — will investigate and defend this claim so that this case is resolved as soon as legally practical.”

U.S. Stem Cell and its affiliated entities did not administer the treatment to the patient. The procedure was performed by an outside practitioner, who is among the hundreds of trained doctors worldwide who utilize U.S. Stem Cell, Inc. technology. U.S. Stem Cell does not currently treat eye patients, and for nearly 20 years, clinics have safely conducted thousands of stem cell procedures utilizing our protocol. We remain committed to the development of effective cell technologies to treat patients with a variety of diseases and injuries.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.

MIAMI, FL –Nov. 28, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Chief Science Officer Dr. Kristin Comella will present clinical data demonstrating safety and efficacy of its proprietary Adipocell TM therapy in treating degenerative disc disease — a condition that affects more than 65 million Americans annually 1 — at the Annual Meeting for International Federation for Adipose Therapeutics and Science (IFATS).

Dr. Comella, who is a global leader in the development of revolutionary holistic stem cell therapies, will discuss her paper “Effects of the Intradiscal Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in Patients With Degenerative Disc Disease,” on Thursday, November 30, 5:30 p.m., at the Lowes Hotel Miami Beach. Dr.
Comella’s presentation will also be live streamed at www.facebook.com/comella.stem.cell/.

The study, which included 15 patients with degenerative disc disease, featured the use of USRM’s proprietary Adipocell TM therapy following a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue. Adipocell TM kits and enzyme were used to separate and isolate a patient’s own stromal vascular fraction (SVF) which was then delivered into the disc of patients. Patients were then monitored for 6 months for adverse events, range of motion, visual analog scale (VAS), present pain intensity (PPI), Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), Dallas Pain Questionnaire and Short Form (SF)-12 scores. Safety events were also monitored, for a 12-month period.

The procedure demonstrated a strong safety profile with no severe adverse events (SAEs) or complications linked to the therapy they received, and no incidences of infection. Patients who participated in this study experienced statistically significant improvements in several parameters including flexion, pain ratings, VAS, PPI, and short form questionnaires. In addition, both ODI and BDI data was trending positive and a majority of patients reported improvements in their Dallas Pain Questionnaire scores. More importantly, patients overall were pleased with treatment results.

“We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless,” said Dr. Comella, who co-authored the study along with two colleagues. “We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one.”

IFATS is a non-profit scientific society currently dedicated to scientific areas of interest related to facilitating the development of treatments for excess body fat, the generation of new fat tissue for reconstruction after cancer or birth-related defects and the use of adipose tissue as a source of mesenchymal stem cells that have the potential to regenerate and repair different body tissues.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician/veterinary training and certification and stem cell products and protocols. USRM also provides stem cell banking for patients and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.

1 American Association of Neurological Surgeons & the Congress of Neurological Surgeons.

About U.S. Stem Cell, Inc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Sunrise, FL – Nov. 7, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), international leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine, today announced financial results for the three months ended Sept. 30, 2017.

Revenue increased significantly for the quarter, up 106 percent or $730k from the same quarter last year to $1.5m.  Likewise, for the nine months ended Sept. 30, 2017, revenue also increased 92 percent from $2.1 to $4.04m for the same period last year.

Net increase in gross profits also increased to $1m, a 158 percent increase from the same quarter last year.  Net increase in gross profit also increased 102 percent or $1.4m for the same period in 2016, to $2.8m for 2017.

Cash from operations also increased for the nine months ended, up more than 1004% from negative $113k in 2016 to more than $1m in 2017.  Cash from operations was also up for the three months ended 2017, an increase of more than 368% in 2017, totaling $240k, compared to $52k for the same three months in 2016.

“Our operations are continuing to yield successful results for six straight quarters now, including last quarter which was record breaking, and we are still just getting started,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc.  “The increase in operational success — which includes certifying 700 physicians and 287 clinics in the use of our proprietary stem cell technology — is being bolstered by more than 30 states that are passing laws to allow regenerative, cutting-edge procedures like ours.  It’s an exciting time to be in the marketplace, and we are looking forward to our continued growth.”

On Sept. 1, 2017, the State of Texas joined more than 30 other states by passing HR 810 — a ‘right to try’ law allowing Texans to choose medical procedures like stem cell treatments for certain severe chronic diseases and terminal illnesses that have historically been considered more ‘experimental.’  This legislation paves the way for patients living on borrowed time, that are severely debilitated, or in extreme pain due to an ailment.   As more states join the ranks in approving right-to-try laws, USRM will continue to leverage these legislated opportunities.

“Seeing expansion of our proprietary, stem cell therapy process — which empowers a patient to utilize their own, naturally occurring stem cells to treat chronic pain and other systemic conditions — is such a remarkable experience, ” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc.  “Our ability to teach, train and partner with physicians and clinics, as well as develop our own standalone facilities, gives us a unique opportunity to grow the business in so many ways.”

USRM also strengthened its balance sheet this quarter by converting outstanding debt into equity, an indication of debt holders’ increased confidence in the Company’s ability to enhance shareholder value through operations.  In order to facilitate the debt conversion, on Aug. 31 USRM filed an 8-K with the U.S. Securities and Exchange Commission (SEC), executing a debt restructuring agreement with Hunton & Williams LLP.  As a result of the conversion, USRM facilitated a debt reduced of $393k.  The deal freezes interest payments the Company has on two outstanding notes from 2009.  A copy of the SEC Form 8-K filing is available here.

Operating expenses rose 47 percent, due to a combination of factors including a 103 percent increase in depreciation and one-time costs association with operations including stock-based compensation as a result of the debt reduction and performance bonuses.  Loss from operations decreased $336k from $1.3m in the nine months ended Sept. 30, 2017, compared to $957k for the nine months ended Sept. 30, 2017.  Likewise, long-term debt made a slight increase, mostly due to terms of the sale-leaseback.

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Sunrise, FL – Nov. 1, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening of another regenerative clinic using its proprietary products and services, bringing the number of clinics using its technology to 287.

Regenerative Wellness Clinic (RWC), located in West Palm Beach, represents another addition to USRM’s global distribution platform for its proprietary, stem cell technology, and is a direct result of USRM’s position as the world’s largest educator in stem cell innovation and physician training, with more than 700 USRM certified stem cell physicians globally.

“We are so pleased to hit this next milestone with Regenerative Wellness, and look forward to working closely with this incredible team of experts,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. “Partnering with RWC provides us the opportunity to expand our strategic goal of market penetration while maintaining scalability. This approach is in direct alignment with our longer-term strategy of establishing and maintaining profitability as we grow globally.”

The minimally invasive, proprietary procedure — which utilizes a patient’s own stem-cell-rich adipose or fat tissue – has, management believes, significantly boosted success rate for patient outcomes in a wide variety of indications including pain management, orthopedic, autoimmune, cardiac and other systemic conditions.

The West Palm Beach clinic is spearheaded by Dr. Rosemary Daly, an interventional spine/pain management physician, board certified in Anesthesiology and Pain Medicine. Dr. Daly graduated from the New York College of Osteopathic Medicine, and completed her Anesthesiology residency at the Montefiore Medical Center at the Albert Einstein College of Medicine.

“Being able to offer U.S. Stem Cell’s proprietary process to our patients means we will be able to make more advanced, successful regenerative treatments available to patients in South Florida,” said Dr. Daly. “Moreover, we contend that the minimally invasive treatments applied in an outpatient procedure can help jumpstart the body’s own healing capabilities and provide long-term relief — an advancement which has endless options in the world of pain management.”

“Dr. Daly’s expertise in reducing chronic and debilitating pain makes her a perfect partner for our expansion,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. “We look forward to collaborating with the excellent researchers and physicians on Dr. Daly’s team, as we continue to deepen our expertise of this ground-breaking, regenerative therapy.”

U.S. Stem Cell’s novel advancements in stem cell therapy, in managements’ opinion, could be a significant alternative to the explosive opioid crisis in America — a direct results of America’s failed attempt at pain management. According to The New York Times, published June 5, 2017, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017, edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry and has, to management’s knowledge, completed more clinical treatments than any other stem cell company in the world in the past 20 years.

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Sunrise, FL – October 26, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients, as well as a developer of novel autologous cell therapies is proud to congratulate its CEO, Mike Tomas, for his committed advocacy and ongoing support of PACE Center for Girls Miami, a philanthropic organization devoted to serving at-risk adolescent girls. Mr. Tomas will be recognized at the 4th Annual BELIEVING IN GIRLS LUNCHEON on October 25th for his continued leadership, vision, and positive involvement in the organization . As a Founding Board Member of PACE Miami, Mr. Tomas has helped paved the way for the at-risk teen girls’ centerorganization to thrive within the South Florida community.

“We are incredibly grateful to Mike Tomas for his vision and leadership in helping launch PACE Miami to become the thriving organization it is, that today serves 60 at-risk teen girls each year with comprehensive programs of education and counseling. Mike helped make PACE Miami a reality and it would not be as strong as it is today without his ongoing support and guidance,” said Sherry Thompson Giordano, Executive Director of PACE Miami. “Mike is and continues to be a guiding force for PACE Miami every day.”

The 4th Annual Believing in Girls PACE Miami Luncheon today will be a dynamic gathering of community leaders, corporate executives and socially-minded donors who will gather to celebrate the PACE Miami girls and help raise funds for the continued growth of the Center.

Community leaders and donors believe in the mission of PACE Miami to serve at-risk teen girls from 11-17 years old in helping them achieve their full potential in a safe and supportive ways, with a strength-based academic and counseling center.

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

About PACE Center for Girls, Inc. Miami

One of the 19 PACE Centers across the state of Florida, PACE Miami opened its doors on its current location at 1400 NW 36th Street, on March 6, 2014. PACE Miami provides girls and young women from the ages of 11-17 an opportunity for a better future through education, counseling, training and advocacy at a full academic and counseling center where girls attend full school day programs. For further information, please visit PACE Center MIAMI.

Sunrise, FL – October 10, 2017 – (OTC:USRM) U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, announced today that its Chief Science Officer Kristin Comella, PhD, will present on October 13 th at Bulletproof’s 5 th Annual Biohacking Conference in Pasadena, CA. Dr. Comella’s presentation will be live- streamed, starting at 3:15 p.m. PT via Facebook Live on the U.S. Stem Cell, Inc. Facebook Page at https://www.facebook.com/USStemCellInc/.

Dr. Comella’s participation is part of U.S. Stem Cell, Inc.’s ongoing effort to educate consumers on the power of using their body’s own healing potential through regenerative medicine. At the Biohacking Conference, Dr. Comella will be joining an informational Stem Cell Panel led by Harry Adelson, ND, an expert in stem cell therapy and the founder of Docere Clinics in Park City, Utah. This will be Dr. Comella’s second consecutive appearance at the Biohacking Conference.

Dr. Comella’s invitations to speak at the Bulletproof Conference follow a stem cell treatment Bulletproof Founder Dave Asprey received at U.S. Stem Cell Clinic back in July 2016, when he live-streamed the procedure on Facebook. U.S. Stem Cell Clinic is 33.3% owned by U.S. Stem Cell, Inc. To watch the recoded version of Asprey’s Facebook Live video, click here: https://tinyurl.com/y7vjqwfd.

Dr. Comella is a world-renowned expert on regenerative medicine with a focus on adipose derived stem cells. She was named number 24 on Terrapin’s list of the Top 50 Global Stem Cell Influencers and number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Most recently, Dr. Comella made the list of Top 50 Functional and Integrative Medical Doctors in the country by DrAxe.com, one of the most visited natural health websites in the world.

“I am excited and honored to be a part of the Bulletproof Conference that brings together some of the brightest minds in the regenerative industry who are pushing the limits of what the human mind and body can do,” Dr. Comella said in a statement. “Please tune in on Facebook Live at 3:15 pm PT on October 13 th to watch the stem cell panel discussion.”

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. Since 1999, the company has completed more clinical treatments (for both humans and animals) than any other regenerative company in the world. U.S. Stem Cell, Inc. is focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. U.S. Stem Cell, Inc. has also partnered with other companies to build a national distribution network for stem cell therapies using the U.S. Stem Cell, Inc. developed technologies and is on track to add an additional 10 stem cell treatment centers and clinics in the U.S.

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine /cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine/ cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward- looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors”; in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Sunrise, FL – September 13, 2017 – (OTC:USRM) U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, today submitted a Form 8-K to the U.S. Securities and Exchange Commission (SEC), reporting a debt restructuring agreement it entered into with Hunton & Williams LLP on August 31, 2017.

The Hunton agreement is part of U.S. Stem Cell, Inc.’s continued effort to clean up the balance sheet and lower the company’s debt. This agreement is estimated to provide a debt relief of approximately $393,180. A copy of the SEC Form 8-K filing is available here.

“Treating patients, generating revenue and restructuring debt has always been a top priority at US Stem Cell Inc,” said the company’s President & CEO Mike Tomas. “Hunton & Williams has been an extraordinary legal partner of the company and we are very grateful for their continued support.  Negotiating the Hunton debt allows the company to freeze the interest payments on two notes from 2009 and begin to work towards paying off this long-standing debt.”

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. Since 1999, the company has completed more clinical treatments (for both humans and animals) than any other regenerative company in the world. U.S. Stem Cell, Inc. is focused on the discovery, development and commercialization of cell-based therapies that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. U.S. Stem Cell, Inc. has also partnered with other companies to build a national distribution network for stem cell therapies using the U.S. Stem Cell, Inc. developed technologies and is on track to add an additional 10 stem cell treatment centers and clinics in the U.S.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Sunrise, FL – September 12, 2017 – (OTC:USRM) U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, announced today that its corporate office, lab and clinic have not been affected by Hurricane Irma and remain fully operational. All U.S. Stem Cell, Inc. facilities, including U.S. Stem Cell Clinic, will re-open on Tuesday, September 12 with regular business hours.

“We are pleased to report that there was no damage caused by Hurricane Irma to the U.S. Stem Cell, Inc. facilities in Florida,” said U.S. Stem Cell, Inc. President & CEO Mike Tomas. “Many of our friends and family were not as fortunate, but we are back to work, helping our patients benefit from the power of stem cells and building a national distribution network for stem cell therapies using technologies developed at U.S. Stem Cell, Inc.”

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. Since 1999, the company has completed more clinical treatments (for both humans and animals) than any other regenerative company in the world. U.S. Stem Cell, Inc. is focused on the discovery, development and commercialization of cell-based therapies that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. U.S. Stem Cell, Inc. has also partnered with other companies to build a national distribution network for stem cell therapies using the U.S. Stem Cell, Inc. developed technologies and is on track to add an additional 10 stem cell treatment centers and clinics in the U.S.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

 Sunrise, FL – August 9, 2017 – U.S. Stem Cell, Inc., a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients, as well as a developer of novel autologous cell therapies, is pleased to announce historic results from operations for the quarter ending June 30, 2017.

“We continue to see improvements in operations and balance sheet performance, specifically in the year-over-year increase in both revenue and profit,” said Mike Tomás, President & CEO of U.S. Stem Cell, Inc. “These positive results can be attributed to growing top line revenues through the expansion of our clinics, clinic partnerships, banking patients’ stem cells for future usage, training physicians and pursuing new international business opportunities for growth.”

U.S. Stem Cell, Inc. strives to provide accomplishments and value for both patients and shareholders. Below are highlights of financial results ending June 30, 2017.

• Revenue up by 104% year-over-year for the quarter:  from $678K in Q2 2016 to 1.38M in Q2 2017
• Revenue up by 83% YTD: from $1.39M this time last year to $2.54M in Q2 2017
• Margin increased from 65% to 71% quarter-to-quarter
• Gross profit up by 122% (or $542K) year-over-year for the quarter: from $442K in Q2 2016 to $985K in Q2 2017
• Gross profit up by 80% (or $796K) YTD:  from $999K this time last year to $1.79M in Q2 2017
• Income from operations increased from a loss of ($259K) in Q2 2016 to a gain of $142K in Q2 2017, a three-month comparison
• Income from operations increased YTD from a loss of ($272K) in Q2 2016 to a gain of $100K in Q2 2017, a six-month comparison
• Cash Flow is positive YTD at Q2 2017 at $785K compared to YTD Q2 2016 at ($165K), a six-month comparison
• Working Capital Deficit down 6.9% from $5.8M in Q2 2016 to $5.4M in Q2 2017

VIEW PDF HERE

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.